



Regd. Office: No. 201 Devavrata, Sector 17, Vashi, Navi Mumbai 400 705.

Corp. Office: "Strides House", Billekahalli, Bannerghatta Road, Bangalore-560 076.

**UNAUDITED CONSOLIDATED FINANCIAL RESULTS
FOR THE QUARTER ENDED SEPTEMBER 30, 2008**

Rs.in Lakhs

Sl. No.	Particulars	UNAUDITED				AUDITED
		3 Months ended 30.09.2008	3 Months ended 30.09.2007	9 Months ended 30.09.2008	9 Months ended 30.09.2007	12 months ended 31.12.2007
1	(a) Net Sales / Income from Operations	27,210.33	20,429.30	73,443.43	54,571.61	72,561.20
	(b) Other Operating Income	968.36	993.74	5,604.41	231.70	1,726.84
	Total Income	28,178.69	21,423.04	79,047.84	54,803.31	74,288.04
2	Expenditure					
	(a) (Increase) / decrease in stock in trade & work in progress	(1,203.80)	(1,110.20)	(4,075.17)	(3,900.97)	(6,173.97)
	(b) Consumption of raw materials	15,317.18	11,271.74	38,642.77	26,651.37	41,593.24
	(c) Purchase of traded goods	496.46	170.16	967.91	353.49	508.55
	(d) Employees cost	4,730.14	4,392.40	13,460.59	11,668.70	16,254.67
	(e) Depreciation	750.41	1,114.20	2,866.93	3,021.46	3,771.38
	(f) Other Expenditure	6,475.75	5,091.20	17,598.78	14,367.62	22,621.65
	Total Expenditure	26,566.14	20,929.50	69,461.81	52,161.67	78,575.52
3	Profit / (Loss) from Operations before Other Income, Interest & Exceptional Items (1-2)	1,612.55	493.54	9,586.03	2,641.64	(4,287.48)
4	Other Income (net)	17,060.15	-	22,897.60	-	9,789.46
5	Profit / (Loss) before Interest & Exceptional Items (3+4)	18,672.70	493.54	32,483.63	2,641.64	5,501.98
6	Interest	1,356.42	1,696.30	3,987.22	4,570.41	5,967.60
7	Profit / (Loss) after Interest but before Exceptional Items (5-6)	17,316.28	(1,202.76)	28,496.41	(1,928.77)	(465.62)
8	Exceptional Items					
	- Exchange Fluctuation loss / (gain)	6,953.95	(386.66)	16,616.67	(3,335.68)	(2,407.35)
	- Plant shut down cost & impairment in investments	-	-	-	-	5,398.47
9	Profit / (Loss) from ordinary activities before tax (7-8)	10,362.33	(816.10)	11,879.74	1,406.91	(3,456.74)
10	Tax Expenses	59.61	373.90	999.35	639.45	1,708.57
11	Net Profit / (Loss) from ordinary activities after tax (9-10)	10,302.72	(1,190.00)	10,880.39	767.46	(5,165.31)
12	Extraordinary Item	-	-	-	-	-
13	Net Profit / (Loss) for the period (11-12)	10,302.72	(1,190.00)	10,880.39	767.46	(5,165.31)
	(a) Share of Minority Interest	(232.18)	286.70	(29.60)	94.72	152.71
	(b) Share in associate	-	-	-	-	0.64
14	Consolidated Profit / (Loss) after Minority Interest & Share from Associates	10,534.90	(903.30)	10,909.99	862.18	(5,011.96)
15	Paid-up Equity Share Capital (Face value of Rs.10/-each)	4,005.00	3,500.40	4,005.00	3,500.40	3,500.40
16	Reserves excluding revaluation reserves					17,296.38
17	Basic & Diluted EPS (Rs.) (Not Annualised)					
	(a) Basic EPS	25.51	(2.83)	27.72	1.67	(15.57)
	(b) Diluted EPS	18.95	(2.83)	21.00	1.53	(15.57)
18	Aggregate of Public shareholding :					
	(a) Number of shares	30,628,013	28,314,149	30,628,013	28,314,149	28,417,595
	(b) Percentage of shareholding	76.47%	80.89%	76.47%	80.89%	81.18%

Notes :

- Pursuant to the provisions of clause 41 of the listing agreement, the Company has opted to publish only the Consolidated results. The standalone results of the Company can be viewed on the Company's website www.stridesarco.com, or on the websites of BSE (www.bseindia.com) or NSE (www.nseindia.com).
- The above consolidated results have been extracted from the consolidated financial statement prepared in accordance with principles set out in the Accounting Standard - 21 on Consolidated financial statements, Accounting standard - 23 on Accounting for investments in Associates and Accounting standard - 27 Accounting for investments in Joint ventures
- The above Consolidated results for the period ended September 30, 2008 were reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on October 31, 2008.
- The Statutory Auditors have carried out a limited review of the consolidated unaudited results for the nine months ended September 30, 2008
- During the quarter, Linkace Limited, Cyprus, a wholly owned subsidiary:
 - completed acquisition of controlling interest in Ascent Pharmahealth Limited (formerly Genepharm Australasia Limited), Australia.
 - sold 81% stake in Strides Italia S.r.l, Italy.
- During the quarter, Starsmore Limited, Cyprus, a wholly owned subsidiary :
 - ceded controlling interest in the Latin American Ventures and now hold 49% equity in the Ventures for a transition period until June 30, 2009 when the company intends to sell the remaining 49% to Aspen Pharmacare Holdings Limited, South Africa, for an agreed multiple of EBITDA.
 - Consequently, the Latin American Ventures have not been consolidated effective July 1, 2008.
- Exchange fluctuation loss / (gain) is on account of restatement of Foreign Currency Convertible Bonds, External Commercial Borrowings and 'Mark to Market' (MTM) loss on derivative and option contracts.
- The Company has one derivative contract on which the determination of liability, if any, is dependant on the occurrence of future uncertain events relating to the foreign exchange rates prevailing in June / July 2010 due to which, a reliable estimate of the losses (if any) cannot be made now. Hence, no provision has been made for an amount of Rs.1,288.82 lakhs for the nine months ended September 30, 2008, being the 'Mark to Market' loss, indicated by the Bank as on September 30, 2008.
- In July 2008, 665,000 options were issued to certain eligible employees under the Strides Arcolab ESOP 2008 Scheme.
- The Company operates exclusively in the Pharmaceuticals business segment and as such there is no reportable segment information as per Accounting Standard 17.
- Investor grievances received and disposed off during the quarter ended September 30, 2008
 - Pending complaints at the beginning of the quarter - Nil
 - No. of Complaints received - 11
 - Complaints disposed - 11
 - Complaints unresolved - Nil
- Previous year's / period's figures have been recast / restated wherever necessary to conform to the current year's/period's classification.

For and on behalf of the Board

**Bangalore
October 31, 2008**

**Arun Kumar
Executive Vice Chairman & Managing Director**